Translational research in late-life mood disorders: Implications for future intervention and prevention research

Neuropsychopharmacology

Volumn 32, Issue 9, 2007, Pages 1857-1875

  Smith, Gwenn S ^a,b   Gunning Dixon, Faith M ^c   Lotrich, Francis E ^d   Taylor, Warren D ^e   Evans, Jovier D ^f  

^a UNIVERSITY OF TORONTO   (Canada)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Genetics; Geriatric depression; Magnetic resonance imaging; Neuropsychology; Positron emission tomography (PET); Psychopharmacology

Indexed keywords

AGED; AGING; CEREBROVASCULAR DISEASE; CLINICAL RESEARCH; COMORBIDITY; CONTINUING EDUCATION; DEPRESSION; DISEASE COURSE; ENVIRONMENTAL FACTOR; GENETIC RISK; GERIATRIC DISORDER; GERONTOPSYCHIATRY; HEALTH CARE ORGANIZATION; HUMAN; MOOD DISORDER; NERVE DEGENERATION; NEUROIMAGING; NEUROPSYCHOLOGY; NEUROSCIENCE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYMPTOMATOLOGY;

BIOMEDICAL RESEARCH; GERIATRICS; HEALTH SERVICES RESEARCH; HUMANS; MOOD DISORDERS;

EID: 34547918348     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301333     Document Type: Review

References (258)

1. Adler CM, DelBello MP, Strakowski SM (2006). Brain network dysfunction in bipolar disorder. CNS Spectr 11: 312-320.
2. Agren H, Reibring L (1994). PET studies of presynaptic monoamine metabolism in depressed patients and healthy volunteers. Pharmacopsychiatry 27: 2-6.
3. 11C]5-hydroxytryptophan in major depression: a positron emission tomography study on patients and healthy volunteers. Acta Psychiatr Scand 83: 449-455.
4. Aizenstein H, Butters MA, Cochran JL, Zmuda MD, Stenger VA, Becker JT (2005a). Prefrontal and Anterior Cingulate Cortex Functioning during Cognitive Control in Late-Life Depression. Presented at American Association of Geriatric Psychiatry Meeting. Lippincott Williams & Wilkins: San Diego, CA.
5. Aizenstein HJ, Butters MA, Figurski JL, Stenger VA, Reynolds III CF, Carter CS (2005b). Prefrontal and striatal activation during sequence learning in geriatric depression. Biol Psychiatry 58: 290-296.
6. Alexopoulos GS (2002). Frontostriatal and limbic dysfunction in late-life depression. Am J Geriatr Psychiatry 10:687-695.
7. Alexopoulos GS (2005). Depression in the elderly. Lancet 365: 1961-1970.
8. Alexopoulos GS, Kiosses DN, Choi SJ, Murphy CF, Lim KO (2002). Frontal white matter microstructure and treatment response of late-life depression: a preliminary study. Am J Psychiatry 159: 1929-1932.
9. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M (1997a). Vascular depression hypothesis. Arch Gen Psychiatry 54: 915-922.
10. Alexopoulos GS, Meyers BS, Young RC, Kakuma T, Feder M, Einhorn A et al (1996a). Recovery in geriatric depression. Arch Gen Psychiatry 53: 305-312.
11. Alexopoulos GS, Meyers BS, Young RC, Kakuma T, Silbersweig D, Charlson M (1997b). Clinically defined vascular depression. Am J Psychiatry 154: 562-565.
12. Alexopoulos GS, Vrontou C, Kakuma T, Meyers BS, Young RC, Klausner E et al (1996b). Disability in geriatric depression. Am J Psychiatry 153: 877-885.
13. Alfonso J, Pollevick GD, Van Der Hart MG, Flugge G, Fuchs E, Frasch AC (2004). Identification of genes regulated by chronic psychosocial stress and antidepressant treatment in the hippocampus. Eur J Neurosci 19: 659-666.
14. Altar CA, Laeng P, Jurata LW, Brockman JA, Lemire A, Bullard J et al (2004). Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways. J Neurosci 24: 2667-2677.
15. Altshuler D, Brooks LD, Chakravati A, Collins FS, Daly MJ, Donnelly P (2005). A haplotype map of the human genome. Nature 437: 1299-1320.
16. Anand A, Verhoeff P, Seneca N, Zoghbi SS, Seibyl JP, Charney DS et al (2000). Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry 157: 1108-1114.
17. Antai-Otong D (2004). Poststroke depression: psychopharmacological considerations. Perspect Psychiatr Care 40: 167-170.
18. Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R et al (2006). Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology (E-pub ahead of print, 25 October 2006).
19. Arango V, Underwood MD, Mann JJ (2002). Serotonin brain circuits involved in major depression and suicide. Prog Brain Res 136: 443-453.
20. Arean PA, Reynolds III CF (2005). The impact of psychosocial factors on late-life depression. Biol Psychiatry 58: 277-282.
21. Arfken CL, Lichtenberg PA, Tancer ME (1999). Cognitive impairment and depression predict mortality in medically ill older adults. J Gerontol A Biol Sci Med Sci 54: M152-M156.
22. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L (2005). Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. J Psychopharmacol 19: 166-172.
23. Ashtari M, Greenwald BS, Kramer-Ginsberg E, Hu J, Wu H, Patel M et al (1999). Hippocampal/amygdala volumes in geriatric depression. Psychol Med 29: 629-638.
24. Ballmaier M, Toga AW, Blanton RE, Sowell ER, Lavretsky H, Peterson J et al (2004). Anterior cingulate, gyrus rectus, and orbitofrontal abnormalities in elderly depressed patients: an MRI-based parcellation of the prefrontal cortex. Am J Psychiatry 161: 99-108.
25. Bell-McGinty S, Butters MA, Meltzer CC, Greer PJ, Reynolds III CF, Becker JT (2002). Brain morphometric abnormalities in geriatric depression: long-term neurobiological effects of illness duration. Am J Psychiatry 159: 1424-1427.
26. Binder EB, Holsboer F (2006). Pharmacogenomics and antidepressant drugs. Ann Med 38: 82-94.
27. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B et al (2004). Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 36: 1319-1325.
28. Bremner JD, Vythilingam M, Vermetten E, Nazeer A, Adil J, Khan S et al (2002). Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry 51: 273-279.
29. Brody AL, Mandelkern MA, Olmstead RE, Scheibal D, Hahn E, Shiraga S et al (2006). Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch Gen Psychiatry 63: 808-816.
30. Brown SM, Peet E, Manuck SB, Williamson DE, Dahl RE, Ferrell RE et al (2005). A regulatory variant of the human tryptophan hydroxylase-2 gene biases amygdala reactivity. Mol Psychiatry 10: 805, 884-888.
31. Bruce ML, Leaf PJ (1989). Psychiatric disorders and 15-month mortality in a community sample of older adults. Am J Public Health 79: 727-730.
32. Bunney WE, Bunney BG, Vawter MP, Tomita H, Li J, Evans SJ et al (2003). Microarray technology: a review of new strategies to discover candidate vulnerability genes in psychiatric disorders. Am J Psychiatry 160: 657-666.
33. Butters MA, Becker JT, Nebes RD, Zmuda MD, Mulsant BH, Pollock BG et al (2000). Changes in cognitive functioning following treatment of late-life depression. Am J Psychiatry 157: 1949-1954.
34. Butters MA, Bhalla RK, Mulsant BH, Mazumdar S, Houck PR, Begley AE et al (2004). Executive functioning, illness course, and relapse/recurrence in continuation and maintenance treatment of late-life depression: is there a relationship? Am J Geriatr Psychiatry 12: 387-394.
35. Cabeza R, Anderson ND, Houle S, Mangels JA, Nyberg L (2000). Age-related differences in neural activity during item and temporal-order memory retrieval: a positron emission tomography study. J Cogn Neurosci 12: 197-206.
36. Cabeza R, Anderson ND, Locantore JK, McIntosh AR (2002). Aging gracefully: compensatory brain activity in high-performing older adults. Neuroimage 17: 1394-1402.
37. Cabeza R, Daselaar SM, Dolcos F, Prince SE, Budde M, Nyberg L (2004). Task-independent and task-specific age effects on brain activity during working memory, visual attention and episodic retrieval. Cereb Cortex 14: 364-375.
38. Callicott JH, Straub RE, Pezawas L, Egan MF, Mattay VS, Hariri AR et al (2005). Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc Natl Acad Sci USA 102: 8627-8632.
39. Canli T, Cooney RE, Goldin P, Shah M, Sivers H, Thomason ME et al (2005). Amygdala reactivity to emotional faces predicts improvement in major depression. Neuroreport 16: 1267-1270.
40. Canli T, Sivers H, Thomason ME, Whitfield-Gabrieli S, Gabrieli JD, Gotlib IH (2004). Brain activation to emotional words in depressed vs healthy subjects. Neuroreport 15: 2585-2588.
41. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H et al (2003). Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301: 386-389.
42. Chen B, Wang JF, Sun X, Young LT (2003). Regulation of GAP-43 expression by chronic desipramine treatment in rat cultured hippocampal cells. Biol Psychiatry 53: 530-537.
43. Chen CS, Tsai JC, Tsang HY, Kuo YT, Lin HF, Chiang IC et al (2005). Homocysteine levels, MTHFR C677 T genotype, and MRI Hyperintensities in late-onset major depressive disorder. Am J Geriatr Psychiatry 13: 869-875.
44. Cole MG, Dendukuri N (2003). Risk factors for depression among elderly community subjects: a systematic review and metaanalysis. Am J Psychiatry 160: 1147-1156.
45. Conwell Y, Duberstein PR, Cox C, Herrmann JH, Forbes NT, Caine ED (1996). Relationships of age and axis I diagnoses in victims of completed suicide: a psychological autopsy study. Am J Psychiatry 153: 1001-1008.
46. Craig DW, Stephan DA (2005). Applications of whole-genome high-density SNP genotyping. Expert Rev Mol Diagn 5: 159-170.
47. Craddock N, Forty L (2006). Genetics of affective (mood) disorders. EJHG 14: 660-668.
48. Cryan JF, Holmes A (2005). The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 4: 775-790.
49. Cryan JF, Valentino RJ, Lucki I (2005). Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 29: 547-569.
50. Davidson RJ, Irwin W, Anderle MJ, Kalin NH (2003). The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry 160: 64-75.
51. de Asis JM, Stern E, Alexopoulos GS, Pan H, Van Gorp W, Blumberg H et al (2001). Hippocampal and anterior cingulate activation deficits in patients with geriatric depression. Am J Psychiatry 158: 1321-1323.
52. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA et al (2002). Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51: 145-155.
53. Dew MA, Reynolds III CF, Houck PR, Hall M, Buysse DJ, Frank E et al (1997). Temporal profiles of the course of depression during treatment. Predictors of pathways toward recovery in the elderly. Arch Gen Psychiatry 54: 1016-1024.
54. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13: 350-356.
55. Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ et al (1999). PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 46: 1375-1387.
56. Duman RS, Heninger GR, Nestler EJ (1997). A molecular and cellular theory of depression. Arch Gen Psychiatry 54: 597-606.
57. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A et al (2003). The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112: 257-269.
58. Ehm MG, Nelson MR, Spurr NK (2005). Guidelines for conducting and reporting whole genome/large-scale association studies. Hum Mol Genet 14: 2485-2488.
59. Elderkin-Thompson V, Kumar A, Bilker WB, Dunkin JJ, Mintz J, Moberg PJ et al (2003). Neuropsychological deficits among patients with late-onset minor and major depression. Arch Clin Neuropsychol 18: 529-549.
60. Elderkin-Thompson V, Kumar A, Mintz J, Boone K, Bahng E, Lavretsky H (2004). Executive dysfunction and visuospatial ability among depressed elders in a community setting. Arch Clin Neuropsychol 19: 597-611.
61. Elliott R, Rubinsztein JS, Sahakian BJ, Dolan RJ (2002). The neural basis of mood-congruent processing biases in depression. Arch Gen Psychiatry 59: 597-604.
62. Erraji-Benchekroun L, Underwood MD, Arango V, Galfalvy H, Pavlidis P, Smyrniotopoulos P et al (2005). Molecular aging in human prefrontal cortex is selective and continuous throughout adult life. Biol Psychiatry 57: 549-558.
63. Evans SJ, Choudary PV, Neal CR, Li JZ, Vawter MP, Tomita H et al (2004). Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci USA 101: 15506-15511.
64. Fan J, McCandliss BD, Sommer T, Raz A, Posner MI (2002). Testing the efficiency and independence of attentional networks. J Cogn Neurosci 14: 340-347.
65. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992). Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49: 538-544.
66. Firbank MJ, Lloyd AJ, Ferrier N, O'Brien JT (2004). A volumetric study of MRI signal hyperintensities in late-life depression. Am J Geriatr Psychiatry 12: 606-612.
67. Flint AJ (1994). Epidemiology and comorbidity of anxiety disorders in the elderly. Am J Psychiatry 151: 640-649.
68. Flint AJ (1998). Management of anxiety in late-life. J Geriatr Psychiatry Neurol 11: 194-200.
69. Flint AJ, Rifat SL (1999). Recurrence of first-episode geriatric depression after discontinuation of maintenance antidepressants. Am J Psychiatry 156: 943-945.
70. Fowler JS, Ding YS, Volkow ND (2003). Radiotracers for positron emission tomography imaging. Semin Nucl Med 33: 14-27.
71. Frodl T, Meisenzahl EM, Zill P, Baghai T, Rujescu D, Leinsinger G et al (2004). Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression. Arch Gen Psychiatry 61: 177-183.
72. Fujikawa T, Yokota N, Muraoka M, Yamawaki S (1996). Response of patients with major depression and silent cerebral infarction to antidepressant drug therapy, with emphasis on central nervous system adverse reactions. Stroke 27: 2040-2042.
73. Gallagher D, Rose J, Rivera P, Lovett S, Thompson LW (1989). Prevalence of depression in family caregivers. Gerontologist 29: 449-456.
74. George AE, de Leon MJ, Gentes CI, Miller J, London E, Budzilovich GN et al (1986a). Leukoencephalopathy in normal and pathologic aging: 1. CT of brain lucencies. AJNR 7: 561-566.
75. George AE, de Leon MJ, Kalnin A, Rosner L, Goodgold A, Chase N (1986b). Leukoencephalopathy in normal and pathologic aging: 2. MRI of brain lucencies. AJNR 7: 567-570.
76. Gladkevich A, Kauffman HF, Korf J (2004). Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 28: 559-576.
77. Glaser R, Robles TF, Sheridan J, Malarkey WB, Kiecolt-Glaser JK (2003). Mild depressive symptoms are associated with amplified and prolonged inflammatory responses after influenza virus vaccination in older adults. Arch Gen Psychiatry 60: 1009-1014.
78. Glatz K, Mossner R, Heils A, Lesch KP (2003). Glucocorticoid-regulated human serotonin transporter (5-HTT) expression is modulated by the 5-HTT gene-promotor-linked polymorphic region. J Neurochem 86: 1072-1078.
79. Greenwald BS, Kramer-Ginsberg E, Krishnan KR, Ashtari M, Auerbach C, Patel M (1998). Neuroanatomic localization of magnetic resonance imaging signal hyperintensities in geriatric depression. Stroke 29: 613-617.
80. Greenwald BS, Kramer-Ginsberg E, Krishnan RR, Ashtari M, Aupperle PM, Patel M (1996). MRI signal hyperintensities in geriatric depression. Am J Psychiatry 153: 1212-1215.
81. Greenwood TA, Kelsoe JR (2003). Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene. Genomics 82: 511-520.
82. Gron G, Bittner D, Schmitz B, Wunderlich AP, Riepe MW (2002). Subjective memory complaints: objective neural markers in patients with Alzheimer's disease and major depressive disorder. Ann Neurol 51: 491-498.
83. Groom GN, Junck L, Foster NL, Frey KA, Kuhl DE (1995). PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease. J Nucl Med 36: 2207-2210.
84. Gunning-Dixon FM, Gur RC, Perkins AC, Schroeder L, Turner T, Turetsky BI et al (2003). Age-related differences in brain activation during emotional face processing. Neurobiol Aging 24: 285-295.
85. Gunning-Dixon FM, Hoptman MJ, D K, Sangoi R, Mack D, Alexopoulos GS (2005). Abnormal frontolimbic activation in late-life. Poster presented at the 5th Annual International College Geriatric Psychoneuropharmacology Meeting Pittsburgh, PA, November 2-5, 2005.
86. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD et al (2001). Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 98: 4746-4751.
87. Hariri AR, Drabant EM, Munoz KE, Kolachana BS, Mattay VS, Egan MF et al (2005). A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry 62: 146-152.
88. Hariri AR, Drabant EM, Weinberger DR (2006). Imaging genetics: perspectives from studies of genetically driven variation in serotonin function and corticolimbic affective processing. Biol Psychiatry 59: 888-897.
89. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF et al (2003). Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 23: 6690-6694.
90. Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D et al (2002). Serotonin transporter genetic variation and the response of the human amygdala. Science 297: 400-403.
91. Hattori E, Liu C, Zhu H, Gershon ES (2005). Genetic tests of biologic systems in affective disorders. Mol Psychiatry 10: 719-740.
92. Heinz A, Braus DF, Smolka MN, Wrase J, Puls I, Hermann D et al (2005). Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter. Nat Neurosci 8: 20-21.
93. Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, Hommer D et al (2000). A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 47: 643-649.
94. Heinz A, Smolka MN (2006). The effects of catechol O-methyltransferase genotype on brain activation elicited by affective stimuli and cognitive tasks. Rev Neurosci 17: 359-367.
95. Henriksson MM, Marttunen MJ, Isometsa ET, Heikkinen ME, Aro HM, Kuoppasalmi KI et al (1995). Mental disorders in elderly suicide. Int Psychogeriatr 7: 275-286.
96. Hickie I, Scott E, Mitchell P, Wilhelm K, Austin MP, Bennett B (1995). Subcortical hyperintensities on magnetic resonance imaging: clinical correlates and prognostic significance in patients with severe depression. Biol Psychiatry 37: 151-160.
97. Hirvonen M, Laakso A, Nagren K, Rinne JO, Pohjalainen T, Hietala J (2004). C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol Psychiatry 9: 1060-1061.
98. Ho BC, Wassink TH, O'Leary DS, Sheffield VC, Andreasen NC (2005). Val158Met gene polymorphism in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow. Mol Psychiatry 10: 229, 287-298.
99. Hume S, Hirani E, Opacka-Juffry J, Myers R, Townsend C, Pike V et al (2001). Effect of 5-HT on binding of [(11)C] WAY 100635 to 5-HT(IA) receptors in rat brain, assessed using in vivo microdialysis nd PET after fenfluramine. Synapse 41: 150-159.
100. Iidaka T, Okada T, Murata T, Omori M, Kosaka H, Sadato N et al (2002). Age-related differences in the medial temporal lobe responses to emotional faces as revealed by fMRI. Hippocampus 12: 352-362.
101. Illman J, Corringham R, Robinson Jr D, Davis HM, Rossi JF, Cella D et al (2005). Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J Support Oncol 3: 37-50.
102. Insel TR, Quirion R (2005). Psychiatry as a clinical neuroscience discipline. JAMA 294: 2221-2224.
103. Jacobs BL, Praag H, Gage FH (2000). Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry 5: 262-269.
104. Jorm AF, van Duijn CM, Chandra V, Fratiglioni L, Graves AB, Heyman A et al (1991). Psychiatric history and related exposures as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 20(Suppl 2): S43-S47.
105. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP et al (2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319.
106. Koschack J, Irle E (2005). Small hippocampal size in cognitively normal subjects with coronary artery disease. Neurobiol Aging 26: 865-871.
107. Kramer-Ginsberg E, Greenwald BS, Krishnan KR, Christiansen B, Hu J, Ashtari M et al (1999). Neuropsychological functioning and MRI signal hyperintensities in geriatric depression. Am J Psychiatry 156: 438-444.
108. Kravitz HM, Janssen I, Lotrich FE, Kado DM, Bromberger JT (2006). Sex steroid hormone gene polymorphisms and depressive symptoms in women at midlife. Am J Med 119(Suppl 1): S87-S93.
109. Krishnan KR (1993). Neuroanatomic substrates of depression in the elderly. J Geriatr Psychiatry Neurol 6: 39-58.
110. Krishnan KR (2002). Biological risk factors in late-life depression. Biol Psychiatry 52: 185-192.
111. Krishnan KR, Hays JC, Blazer DG (1997). MRI-defined vascular depression. Am J Psychiatry 154: 497-501.
112. Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA (2000). Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol 48: 391-395.
113. Kumar A, Bilker W, Jin Z, Udupa J (2000). Atrophy and high intensity lesions: complementary neurobiological mechanisms in late-life major depression. Neuropsychopharmacology 22: 264-274.
114. Kumar A, Gupta RC, Albert Thomas M, Alger J, Wyckoff N, Hwang S (2004). Biophysical changes in normal-appearing white matter and subcortical nuclei in late-life major depression detected using magnetization transfer. Psychiatry Res 130: 131-140.
115. Kumar A, Jin Z, Bilker W, Udupa J, Gottlieb G (1998). Late-onset minor and major depression: early evidence for common neuroanatomical substrates detected by using MRI. Proc Natl Acad Sci USA 95: 7654-7658.
116. Kumar A, Mintz J, Bilker W, Gottlieb G (2002). Autonomous neurobiological pathways to late-life major depressive disorder: clinical and pathophysiological implications. Neuropsychopharmacology 26: 229-236.
117. Lai T, Payne ME, Byrum CE, Steffens DC, Krishnan KR (2000). Reduction of orbital frontal cortex volume in geriatric depression. Biol Psychiatry 48: 971-975.
118. Lamar M, Yousem DM, Resnick SM (2004). Age differences in orbitofrontal activation: an fMRI investigation of delayed match and nonmatch to sample. Neuroimage 21: 1368-1376.
119. Landgrebe J, Welzl G, Metz T, van Gaalen MM, Ropers H, Wurst W et al (2002). Molecular characterisation of antidepressant effects in the mouse brain using gene expression profiling. J Psychiatr Res 36: 119-129.
120. Lavretsky H, Kumar A (2001). Methylphenidate augmentation of citalopram in elderly depressed patients. Am J Geriatr Psychiatry 9: 298-303.
121. Lebowitz BD, Pearson JL, Schneider LS, Reynolds III CF, Alexopoulos GS, Bruce ML et al (1997). Diagnosis and treatment of depression in late-life. Consensus statement update. JAMA 278: 1186-1190.
122. Lee SH, Payne ME, Steffens DC, McQuoid DR, Lai TJ, Provenzale JM et al (2003). Subcortical lesion severity and orbitofrontal cortex volume in geriatric depression. Biol Psychiatry 54: 529-533.
123. Lehtovirta M, Laakso MP, Frisoni GB, Soininen H (2000). How does the apolipoprotein E genotype modulate the brain in aging and in Alzheimer's disease? A review of neuroimaging studies. Neurobiol Aging 21: 293-300.
124. Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD et al (2003). Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci 23: 8788-8799.
125. Lenze EJ, Mulsant BH, Shear MK, Schulberg HC, Dew MA, Begley AE et al (2000). Comorbid anxiety disorders in depressed elderly patients. Am J Psychiatry 157: 722-728.
126. Lenze EJ, Munin MC, Ferrell RE, Pollock BG, Skidmore E, Lotrich F et al (2005). Association of the serotonin transporter gene-linked polymorphic region (5-HTTLPR) genotype with depression in elderly persons after hip fracture. Am J Geriatr Psychiatry 13: 428-432.
127. Leonardo ED, Hen R (2006). Genetics of affective and anxiety disorders. Annu Rev Psychol 57: 117-137.
128. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S et al (1996). Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527-1531.
129. Lesch KP, Gutknecht L (2004). Focus on The 5-HT1A receptor: emerging role of a gene regulatory variant in psychopathology and pharmacogenetics. Int J Neuropsychopharmacol 7: 381-385.
130. Lesch KP, Gutknecht L (2005). Pharmacogenetics of the serotonin transporter. Prog Neuropsychopharmacol Biol Psychiatry 29: 1062-1073.
131. Lesser IM, Boone KB, Mehringer CM, Wohl MA, Miller BL, Berman NG (1996). Cognition and white matter hyperintensities in older depressed patients. Am J Psychiatry 153: 1280-1287.
132. Leuchter AF, Cook IA, Uijtdehaage SH, Dunkin J, Lufkin RB, Anderson-Hanley C et al (1997). Brain structure and function and the outcomes of treatment for depression. J Clin Psychiatry 58(Suppl 16): 22-31.
133. Levinson DF (2006). The genetics of depression: a review. Biol Psychiatry 60: 84-92 (E-pub 21 November 2005).
134. Little JT, Reynolds III CF, Dew MA, Frank E, Begley AE, Miller MD et al (1998). How common is resistance to treatment in recurrent, nonpsychotic geriatric depression? Am J Psychiatry 155: 1035-1038.
135. Lockwood KA, Alexopoulos GS, Kakuma T, Van Gorp WG (2000). Subtypes of cognitive impairment in depressed older adults. Am J Geriatr Psychiatry 8: 201-208.
136. Lockwood KA, Alexopoulos GS, van Gorp WG (2002). Executive dysfunction in geriatric depression. Am J Psychiatry 159: 1119-1126.
137. Lotrich FE, Bies RR, Smith GS, Pollock BG (2006). Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. J Psychopharmacol 20: 33-40.
138. Lotrich FE, Pollock BG (2004). Meta-analysis of serotonin transporter polymorphisms and affective disorders. Psychiatr Genet 14: 121-129.
139. Lotrich FE, Pollock BG (2005a). Candidate genes for antidepressant response to selective serotonin reuptake inhibitors. Neuropsychiatric Dis Treat 1: 17-35.
140. Lotrich FE, Pollock BG (2005b). Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol 45: 1106-1122.
141. Lukiw WJ (2004). Gene expression profiling in fetal, aged, and Alzheimer hippocampus: a continuum of stress-related signaling. Neurochem Res 29: 1287-1297.
142. Macfall JR, Taylor WD, Rex DE, Pieper S, Payne ME, McQuoid DR et al (2005). Lobar distribution of lesion volumes in late-life depression: The Biomedical Informatics Research Network (BIRN). Neuropsychopharmacology 31: 1500-1507.
143. Malison RT, Price LH, Berman R, van Dyck CH, Pelton GH, Carpenter L et al (1998). Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl) tropane and single photon emission computed tomography. Biol Psychiatry 44: 1090-1098.
144. Mann JJ (1998). Neurobiological correlates of the antidepressant action of electroconvulsive therapy. J ECT 14: 172-180.
145. Mayberg HS (2003). Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 65: 193-207.
146. Mazure CM, Maciejewski PK, Jacobs SC, Bruce ML (2002). Stressful life events interacting with cognitive/personality styles to predict late-onset major depression. Am J Geriatr Psychiatry 10: 297-304.
147. Meltzer CC, Price JC, Mathis CA, Greer PJ, Cantwell MN, Houck PR et al (1999). PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am J Psychiatry 156: 1871-1878.
148. Meyer JH, Cho R, Kennedy S, Kapur S (1999). The effects of single dose nefazodone and paroxetine upon 5-HT2A binding potential in humans using [18F]-setoperone PET. Psychopharmacology (Berl) 144: 279-281.
149. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A et al (2006). Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 63: 1209-1216.
150. Meyer JH, Houle S, Sagrati S, Carella A, Hussey DF, Ginovart N et al (2004). Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 61: 1271-1279.
151. Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J et al (2001a). The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatry 158: 78-85.
152. Meyer JH, Kapur S, Houle S, DaSilva J, Owczarek B, Brown GM et al (1999b). Prefrontal cortex 5-HT2 receptors in depression: an [18F]setoperone PET imaging study. Am J Psychiatry 156: 1029-1034.
153. Meyer JH, Kruger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A et al (2001b). Lower dopamine transporter binding potential in striatum during depression. Neuroreport 12: 4121-4125.
154. Meyer JH, McMain S, Kennedy SH, Korman L, Brown GM, DaSilva JN et al (2003). Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry 160: 90-99.
155. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K et al (2001c). Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry 158: 1843-1849.
156. Meyer-Lindenberg A, Weinberger DR (2006). Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 7: 818-827.
157. Meyers BS, Bruce ML (1998). The depression-dementia conundrum: integrating clinical and epidemiological perspectives. Arch Gen Psychiatry 55: 1082-1083.
158. Meyers BS, Flint A, Alastair J, Mulsant BH, Rothschild AJ (2005). The NIMH Stop-PD Trial: Background and Design Choices. Poster presented at the 5th Annual International College Geriatric Psychoneuropharmacology Meeting, Pittsburgh, PA, November 2-5, 2005.
159. Mossner R, Daniel S, Schmitt A, Albert D, Lesch KP (2001). Modulation of serotonin transporter function by interleukin-4. Life Sci 68: 873-880.
160. Murphy CF, Alexopoulos GS (2006). Attention network dysfunction and treatment response of geriatric depression. J Clin Exp Neuropsychol 28: 96-100.
161. Murphy Jr GM, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF (2004). Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 61: 1163-1169.
162. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS et al (2001). Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344: 961-966.
163. Naismith S, Hickie I, Ward PB, Turner K, Scott E, Little C et al (2002). Caudate nucleus volumes and genetic determinants of homocysteine metabolism in the prediction of psychomotor speed in older persons with depression. Am J Psychiatry 159: 2096-2098.
164. Narushima K, Kosier JT, Robinson RG (2002). Preventing poststroke depression: a 12-week double-blind randomized treatment trial and 21-month follow-up. J Nerv Ment Dis 190: 296-303.
165. Nebes RD, Butters MA, Houck PR, Zmuda MD, Aizenstein H, Pollock BG et al (2001). Dual-task performance in depressed geriatric patients. Psychiatry Res 102: 139-151.
166. Nebes RD, Pollock BG, Houck PR, Butters MA, Mulsant BH, Zmuda MD et al (2003). Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine. J Psychiatr Res 37: 99-108.
167. Nemeroff CB, Vale WW (2005). The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry 66(Suppl 7): 5-13.
168. Nielson KA, Langenecker SA, Garavan H (2002). Differences in the functional neuroanatomy of inhibitory control across the adult life span. Psychol Aging 17: 56-71.
169. Nielson KA, Langenecker SA, Ross TJ, Garavan H, Rao SM, Stein EA (2004). Comparability of functional MRI response in young and old during inhibition. Neuroreport 15: 129-133.
170. Nobuhara K, Okugawa G, Sugimoto T, Minami T, Tamagaki C, Takase K et al (2006). Frontal white matter anisotropy and symptom severity of late-life depression: a magnetic resonance diffusion tensor imaging study. J Neurol Neurosurg Psychiatry 77: 120-122.
171. O'Brien JT, Lloyd A, McKeith I, Gholkar A, Ferrier N (2004). A longitudinal study of hippocampal volume, cortisol levels, and cognition in older depressed subjects. Am J Psychiatry 161: 2081-2090.
172. O'Connor MK, Knapp R, Husain M, Rummans TA, Petrides G, Smith G et al (2001). The influence of age on the response of major depression to electroconvulsive therapy: a C.O.R.E. Report. Am J Geriatr Psychiatry 9: 382-390.
173. Paez-Pereda M (2005). New drug targets in the signaling pathways activated by antidepressants. Prog Neuro-Psychopharmacol Biol Psychiatry 29: 1010-1016.
174. Parsey RV, Oquendo MA, Ogden RT, Olvet DM, Simpson N, Huang YY et al (2006). Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry 59: 106-113.
175. Parsey RV, Oquendo MA, Zea-Ponce Y, Rodenhiser J, Kegeles LS, Pratap M et al (2001). Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry 50: 313-322.
176. Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS et al (2005). 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 8: 828-834.
177. Pezawas L, Verchinski BA, Mattay VS, Callicott JH, Kolachana BS, Straub RE et al (2004). The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 24: 10099-10102.
178. Pierpaoli C, Basser PJ (1996). Toward a quantitative assessment of diffusion anisotropy. Magn Reson Med 36: 893-906.
179. Pillay SS, Renshaw PF, Bonello CM, Lafer BC, Fava M, Yurgelun-Todd D (1998). A quantitative magnetic resonance imaging study of caudate and lenticular nucleus gray matter volume in primary unipolar major depression: relationship to treatment response and clinical severity. Psychiatry Res 84: 61-74.
180. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA et al (2000). Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in latelife depression. Neuropsychopharmacology 23: 587-590.
181. Posener JA, Wang L, Price JL, Gado MH, Province MA, Miller MI et al (2003). High-dimensional mapping of the hippocampus in depression. Am J Psychiatry 160: 83-89.
182. Rajkowska G, Miguel-Hidalgo JJ, Dubey P, Stockmeier CA, Krishnan KR (2005). Prominent reduction in pyramidal neurons density in the orbitofrontal cortex of elderly depressed patients. Biol Psychiatry 58: 297-306.
183. Ramasubbu R (2003). Serotonin transporter gene functional polymorphism: a plausible candidate gene for increased vascular risk in depression. Med Hypotheses 61: 36-44.
184. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J (2001). Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA 98: 3334-3339.
185. Reiman EM, Uecker A, Caselli RJ, Lewis S, Bandy D, de Leon MJ et al (1998). Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann Neurol 44: 288-291.
186. Reynolds III CF, Dew MA, Frank E, Begley AE, Miller MD, Cornes C et al (1998). Effects of age at onset of first lifetime episode of recurrent major depression on treatment response and illness course in elderly patients. Am J Psychiatry 155: 795-799.
187. Reynolds III CF, Frank E, Dew MA, Houck PR, Miller M, Mazumdar S et al (1999). Treatment of 70(+)-year-olds with recurrent major depression. Excellent short-term but brittle long-term response. Am J Geriatr Psychiatry 7: 64-69.
188. Reynolds III CF, Frank E, Perel JM, Mazumdar S, Dew MA, Begley A et al (1996). High relapse rate after discontinuation of adjunctive medication for elderly patients with recurrent major depression. Am J Psychiatry 153: 1418-1422.
189. Ricciarelli R, d'Abramo C, Massone S, Marinari U, Pronzato M, Tabaton M (2004). Microarray analysis in Alzheimer's disease and normal aging. IUBMB Life 56: 349-354.
190. Roffman JL, Weiss AP, Goff DC, Rauch SL, Weinberger DR (2006). Neuroimaging-genetic paradigms: a new approach to investigate the pathophysiology and treatment of cognitive deficits in schizophrenia. Harv Rev Psychiatry 14: 78-91.
191. 11C]methyl-L- tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Arch Gen Psychiatry 61: 556-563.
192. Rose EJ, Simonotto E, Ebmeier KP (2006). Limbic over-activity in depression during preserved performance on the n-back task. Neuroimage 29: 203-215.
193. Rybakowski JK, Borkowska A, Czerski PM, Skibinska M, Hauser J (2003). Polymorphism of the brain-derived neurotrophic factor gene and performance on a cognitive prefrontal test in bipolar patients. Bipolar Disord 5: 468-472.
194. Sahakian BJ, Owen AM (1992). Computerized assessment in neuropsychiatry using CANTAB: discussion paper. J R Soc Med 85: 399-402.
195. 11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 57: 174-180.
196. Scarmeas N, Stern Y (2005). Imaging studies and APOE genotype in persons at risk for Alzheimer's disease. Curr Psychiatry Rep 8: 11-17.
197. Schatzberg A, Garlow S, Nemeroff CB (2002). Molecular and cellular mechanisms in depression. In: (Series) Neuropsychopharmacology: The Fifth Generation of Progress. Lippincott Williams & Wilkins: Philadelphia. pp 1039-1050.
198. Schildkraut JJ (1965). The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiat 122: 509-522.
199. Schinka JA, Busch RM, Robichaux-Keene N (2004). A metaanalysis of the association between the serotonin transporter gene polymorphism (5-HTTLPR) and trait anxiety. Mol Psychiatry 9: 197-202.
200. Schulz R, O'Brien AT, Bookwala J, Fleissner K (1995). Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Gerontologist 35: 771-791.
201. Serretti A, Benedetti F, Zanardi R, Smeraldi E (2005). The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Prog Neuropsychopharmacol Biol Psychiatry 29: 1074-1084.
202. Shear K, Frank E, Houck PR, Reynolds III CF (2005). Treatment of complicated grief: a randomized controlled trial. JAMA 293: 2601-2608.
203. Sheline YI, Gado MH, Kraemer HC (2003). Untreated depression and hippocampal volume loss. Am J Psychiatry 160: 1516-1518.
204. Sheline YI, Gado MH, Price JL (1998). Amygdala core nuclei volumes are decreased in recurrent major depression. Neuroreport 9: 2023-2028.
205. Sheline YI, Sanghavi M, Mintun MA, Gado MH (1999). Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 19: 5034-5043.
206. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW (1996). Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 93: 3908-3913.
207. Shioe K, Ichimiya T, Suhara T, Takano A, Sudo Y, Yasuno F et al (2003). No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET. Synapse 48: 184-188.
208. Sibille E, Arango V, Galfalvy HC, Pavlidis P, Erraji-Benchekroun L, Ellis SP et al (2004). Gene expression profiling of depression and suicide in human prefrontal cortex. Neuropsychopharmacology 29: 351-361.
209. Simpson SW, Jackson A, Baldwin RC, Burns A (1997). 1997 IPA/Bayer Research Awards in psychogeriatrics. Subcortical hyperintensities in late-life depression: acute response to treatment and neuropsychological impairment. Int Psychogeriatr 9: 257-275.
210. Smith GS, Kramer E, Hermann CR, Goldberg S, Ma Y, Dhawan V (2000). Evaluation of citalopram as a pharmacologic intervention of the serotonin system. Biol Psychiat 47: S99.
211. Smith GS, Kramer E, Hermann CR, Goldberg S, Ma Y, Dhawan V et al (2002a). Acute and chronic effects of citalopram on cerebral glucose metabolism in geriatric depression. Am J Geriatr Psychiatry 10: 715-723.
212. Smith GS, Lotrich FE, Malhotra AK, Lee AT, Ma Y, Kramer E et al (2004). Effects of serotonin transporter promoter polymorphisms on serotonin function. Neuropsychopharmacology 29: 2226-2234.
213. Smith GS, Ma Y, Dhawan V, Gunduz H, Carbon M, Kirshner M et al (2002b). Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography (PET) in human subjects. Synapse 45: 105-112.
214. Smith GS, Reynolds III CF, Houck PR, Dew MA, Ma Y, Mulsant BH et al (2002c). Glucose metabolic response to total sleep deprivation, recovery sleep, and acute antidepressant treatment as functional neuroanatomic correlates of treatment outcome in geriatric depression. Am J Geriatr Psychiatry 10: 561-567.
215. Smith GS, Reynolds III CF, Pollock B, Derbyshire S, Nofzinger E, Dew MA et al (1999). Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression. Am J Psychiatry 156: 683-689.
216. Steffens DC, Byrum CE, McQuoid DR, Greenberg DL, Payne ME, Blitchington TF et al (2000). Hippocampal volume in geriatric depression. Biol Psychiatry 48: 301-309.
217. Steffens DC, Conway CR, Dombeck CB, Wagner HR, Tupler LA, Weiner RD (2001). Severity of subcortical gray matter hyperintensity predicts ECT response in geriatric depression. J Ect 17: 45-49.
218. Steffens DC, Payne ME, Greenberg DL, Byrum CE, Welsh-Bohmer KA, Wagner HR et al (2002). Hippocampal volume and incident dementia in geriatric depression. Am J Geriatr Psychiatry 10: 62-71.
219. Strauss J, Barr CL, George CJ, King N, Shaikh S, Devlin B et al (2004). Association study of brain-derived neurotrophic factor in adults with a history of childhood onset mood disorder. Am J Med Genet B Neuropsychiatr Genet 131: 16-19.
220. Styner M, Lieberman JA, Pantazis D, Gerig G (2004). Boundary and medial shape analysis of the hippocampus in schizophrenia. Med Image Anal 8: 197-203.
221. Suhara T, Nakayama K, Inoue O, Fukuda H, Shimizu M, Mori A et al (1992). D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology (Berlin) 106: 14-18.
222. Surguladze S, Brammer MJ, Keedwell P, Giampietro V, Young AW, Travis MJ et al (2005). A differential pattern of neural response toward sad versus happy facial expressions in major depressive disorder. Biol Psychiatry 57: 201-209.
223. Sweet RA, Hamilton RL, Butters MA, Mulsant BH, Pollock BG, Lewis DA et al (2004). Neuropathologic correlates of late-onset major depression. Neuropsychopharmacology 29: 2242-2250.
224. Szuba MP, O'Reardon JP, Evans DL (2000). Physiological effects of electroconvulsive therapy and transcranial magnetic stimulation in major depression. Depress Anxiety 12: 170-177.
225. Taylor WD, MacFall JR, Payne ME, McQuoid DR, Provenzale JM, Steffens DC et al (2004). Late-life depression and microstructural abnormalities in dorsolateral prefrontal cortex white matter. Am J Psychiatry 161: 1293-1296.
226. Taylor WD, MacFall JR, Payne ME, McQuoid DR, Steffens DC, Provenzale JM et al (2005a). Greater MRI lesion volumes in elderly depressed subjects than in control subjects. Psychiatry Res 139: 1-7.
227. Taylor WD, Steffens DC, Payne ME, MacFall JR, Marchuk DA, Svenson IK et al (2005b). Influence of serotonin transporter promoter region polymorphisms on hippocampal volumes in late-life depression. Arch Gen Psychiatry 62: 537-544.
228. Tessitore A, Hariri AR, Fera F, Smith WG, Das S, Weinberger DR et al (2005). Functional changes in the activity of brain regions underlying emotion processing in the elderly. Psychiatry Res 139: 9-18.
229. Tew Jr JD, Mulsant BH, Haskett RF, Prudic J, Thase ME, Crowe RR et al (1999). Acute efficacy of ECT in the treatment of major depression in the old-old. Am J Psychiatry 156: 1865-1870.
230. Thomas AJ, Ferrier IN, Kalaria RN, Woodward SA, Ballard C, Oakley A et al (2000). Elevation in late-life depression of intercellular adhesion molecule-1 expression in the dorsolateral prefrontal cortex. Am J Psychiatry 157: 1682-1684.
231. Thomas AJ, O'Brien JT, Davis S, Ballard C, Barber R, Kalaria RN et al (2002). Ischemic basis for deep white matter hyperintensities in major depression: a neuropathological study. Arch Gen Psychiatry 59: 785-792.
232. Thomas AJ, Davis S, Morris C, Jackson E, Harrison R, O'Brien JT (2005). Increase in interleukin-1beta in late-life depression. Am J Psychiatry 162: 175-177.
233. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK et al (1997). D2 dopamine receptor gene (DRD2) Taq1 A Schatzberg A, Garlow S, Nemeroff CB (2002). Molecular and polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7: 479-484.
234. Tiemeier H, Hofman A, van Tuijl HR, Kiliaan AJ, Meijer J, Breteler MM (2003). Inflammatory proteins and depression in the elderly. Epidemiology 14: 103-107.
235. Toescu EC, Verkhratsky A, Landfield PW (2004). Ca2+ regulation and gene expression in normal brain aging. Trends Neurosci 27: 614-620.
236. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P (1998). Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 25(Suppl 1): 39-47.
237. Van Rossum EF, Binder EB, Majer M, Koper JW, Ising M, Modell S et al (2006). Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry 59: 681-688.
238. van West D, Van Den Eede F, Del-Favero J, Souery D, Norrback KF, Van Duijn CM et al (2006). Glucocorticoid receptor gene-based SNP analysis in patient with recurrent major depression. Neuropsychopharmacology 31: 620-627.
239. Vercauterern FG, Bergeron JJ, Vandesande F, Arckens L, Quirion R (2004). Proteomic approaches in brain research and neuropharmacology. Eur J Pharmacol 500: 385-398.
240. Vinkers DJ, Gussekloo J, Stek ML, Westendorp RG, Van Der Mast RC (2004). The 15-item Geriatric Depression Scale (GDS-15) detects changes in depressive symptoms after a major negative life event. The Leiden 85-plus Study. Int J Geriatr Psychiatry 19: 80-84.
241. 11C]raclopride in the human brain. Synapse 16: 255-262.
242. Vythilingam M, Chen J, Bremner JD, Mazure CM, Maciejewski PK, Nelson JC (2003). Psychotic depression and mortality. Am J Psychiatry 160: 574-576.
243. Vythilingam M, Vermetten E, Anderson GM, Luckenbaugh D, Anderson ER, Snow J et al (2004). Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol Psychiatry 56: 101-112.
244. Wakana S, Jiang H, Nagae-Poetscher LM, van Zijl PC, Mori S (2004). Fiber tract-based atlas of human white matter anatomy. Radiology 230: 77-87.
245. Whyte EM, Mulsant BH, Vanderbilt J, Dodge HH, Ganguli M (2004). Depression after stroke: a prospective epidemiological study. J Am Geriatr Soc 52: 774-778.
246. 11C]-(+)-PHNO. Biol Psychiatry 59: 389-394.
247. Willeit M, Stastny J, Pirker W, Praschak-Rieder N, Neumeister A, Asenbaum S et al (2001). No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism. Biol Psychiatry 50: 8-12.
248. Wolkin A, Brodie JD, Barouche F, Rotrosen J, Wolf AP, Smith M et al (1989). Dopamine receptor occupancy and plasma haloperidol levels. Arch Gen Psychiatry 46: 482-484.
249. Wong ML, Licinio J (2004). From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov 3: 136-151.
250. Yamada M, Yamada M, Yamazaki S, Takahashi K, Nara K, Ozawa H et al (2001). Induction of cysteine string protein after chronic antidepressant treatment in rat frontal cortex. Neurosci Lett 301: 183-186.
251. Yamada M, Yamada M, Yamazaki S, Takahashi K, Nishioka G, Kudo K et al (2000). Identification of a novel gene with RING-H2 finger motif induced after chronic antidepressant treatment in rat brain. Biochem Biophys Res Commun 278: 150-157.
252. Yatham LN, Liddle PF, Dennie J, Shiah IS, Adam MJ, Lane CJ et al (1999). Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone. Arch Gen Psychiatry 56: 705-711.
253. Young RC, Gyulai L, Mulsant BH, Flint A, Beyer JL, Shulman KI et al (2004). Pharmacotherapy of bipolar disorder in old age: review and recommendations. Am J Geriatr Psychiatry 12: 342-357.
254. Young RC, Kalayam B, Nambudiri DE, Kakuma T, Alexopoulos GS (1999). Brain morphology and response to nortriptyline in geriatric depression. Am J Geriatr Psychiatry 7: 147-150.
255. Zanardi R, Artigas F, Moresco R, Colombo C, Messa C, Gobbo C et al (2001). Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment: a positron emission tomography scan study. J Clin Psychopharmacol 21: 53-58.
256. Zhang X, Gainetdinov RR, Beaulieu JM, Sotnikova TD, Burch LH, Williams RB et al (2005). Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 45: 11-16.
257. Zill P, Baghai TC, Zwanzger P, Schule C, Eser D, Rupprecht R et al (2004). SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression. Mol Psychiatry 9: 1030-1036.
258. Zubenko GS, Hughes III HB, Maher BS, Stiffler JS, Zubenko WN, Marazita ML (2002). Genetic linkage of region containing the CREB1 gene to depressive disorders in women from families with recurrent, early-onset, major depression. Am J Med Genet 114: 980-987.